Exact Sciences Corp.
EXAS
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
5.1% downsideOvervalued by 5.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $20.03 Billion |
|---|---|
| Enterprise Value | $21.59 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.1 |
| Beta | 1.44 |
| Outstanding Shares | 189,738,000 |
Return
| Return on Equity | -8.66% |
|---|---|
| Return on Assets | -3.55% |
| Return on Invested Capital | -3.44% |
Valuation & Multiples
| P/E Ratio | -95.72 |
|---|---|
| PEG | 106.29 |
| Price to Sales | 6.17 |
| Price to Book Ratio | 8.74 |
| Enterprise Value to Revenue | 6.65 |
| Enterprise Value to EBIT | -120.41 |
| Enterprise Value to Net Income | -104 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 1.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5932▼ 22.17% |
|---|---|
| Total Calls | 3,204,430▲ 50.87% |
| Total Puts | 1,901,000▲ 9.83% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 92.89%▼ 1.43% |
|---|---|
| Total Invested | $17.89B▲ 84.40% |
| Investors Holding | 753▲ 143.00% |
ESG Score
No data
About Exact Sciences Corp.
CEO: Kevin Conroy Relevant Senate Committees
This powerful committee controls taxation and entitlement spending (like Medicare). Changes in tax policy directly affect corporate profitability, and Medicare reimbursement rates are critical for diagnostic companies like Exact Sciences, profoundly impacting their revenue and valuation.
This committee directly regulates the FDA and NIH. FDA approval is critical for Exact Sciences' diagnostic products, and NIH funding impacts the broader biotech research ecosystem. This committee drives stock performance in the sector through drug/device approval oversight.
Members receive classified briefings on global threats, including those potentially affecting critical national capabilities. The description explicitly mentions 'creating high risks for informational asymmetry in defense, cybersecurity, and biotech stocks,' indicating direct relevance to EXAS.